Overview
Artivion Q3 revenue grows 18% yr/yr, beating analyst expectations
Adjusted net income for Q3 beats analyst expectations
Company enrolls first patient in ARTIZEN trial, marking strategic progress
Outlook
Artivion raises full-year 2025 revenue guidance to $439 mln-$445 mln
Company expects 2025 adjusted EBITDA to grow 24%-28%
Artivion anticipates slightly positive currency impact for 2025
Result Drivers
PRODUCT GROWTH - Revenue growth driven by 38% increase in stent grafts and 25% increase in On-X, compared to Q3 2024
FINANCIAL RESTRUCTURING - Refinanced credit agreement to extend maturity date to 2031 and secure a more favorable interest rate
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $113.39 mln | $110.44 mln (7 Analysts) |
Q3 Adjusted Net Income | Beat | $7.90 mln | $1.29 mln (6 Analysts) |
Q3 Net Income | $6.50 mln | ||
Q3 EBIT | $12.54 mln | ||
Q3 Operating Expenses | $65.36 mln | ||
Q3 Pretax Profit | $7.06 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Artivion Inc is $46.00, about 1.1% below its November 5 closing price of $46.51
The stock recently traded at 139 times the next 12-month earnings vs. a P/E of 100 three months ago
Press Release: ID:nPn1NRcjTa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)